HOME >> BIOLOGY >> NEWS
The long road to a promising malaria vaccine started at NYU School of Medicine

NEW YORK, October 15, 2004 -- The malaria vaccine reported today to reduce life-threatening cases of the parasitic disease among children in Mozambique is based on the pioneering research of Drs. Ruth and Victor Nussenzweig and their colleagues at NYU School of Medicine.

Ruth Nussenzweig, Doc en Med, Ph.D., the C.V. Starr Professor of Medical and Molecular Parasitology, and her husband, Victor Nussenzweig, M.D., Ph.D., the Hermann M. Biggs Professor of Preventive Medicine, have devoted decades of research to preventing one of the world's biggest killers. Malaria afflicts hundreds of millions of people, causing up to 3 million deaths every year, mostly in sub-Saharan Africa. Many of its victims are young children.

In a study reported today of more than 2,000 children in Mozambique, the vaccine reduced life-threatening attacks of malaria by 58 percent, and reduced milder forms of the disease by 30 percent. The study is published in the October 16, 2004, issue of The Lancet, a medical journal.

"This is really fantastic news," says Dr. Victor Nussenzweig. "It is the first time that a vaccine has been shown to protect against severe malaria, which is a major cause of death in children in Africa. It is not yet an ideal vaccine because it is expensive, requires three doses, and it isn't known yet how durable the vaccine's protection will be, but it is a very big step forward."

The vaccine, designated RTS.S/AS02A, contains a large portion of a protein called circumsporozoite (CS) protein, which coats malaria parasites that invade the liver. This protein, which the Nussenzweigs first isolated from parasites in 1980, is the basis for some 15 malaria vaccines that now are in clinical trials or in pre-clinical testing.

The vaccine, developed by GlaxoSmithKline in collaboration with the Walter Reed Army Institute of Research, contains a large portion of the CS protein fused with a part of another
'"/>

Contact: Pamela McDonnell
Pamela.McDonnell@med.nyu.edu
212-404-3555
New York University Medical Center and School of Medicine
15-Oct-2004


Page: 1 2 3

Related biology news :

1. A new plant-bacterial symbiotic mechanism promising
2. A new plant-bacterial symbiotic mechanism promising for crop applications
3. American Association for Cancer Research provides support for promising cancer scientists
4. Sea creatures toxin could lead to promising cancer treatment
5. Epigenetic drugs, promising for breast cancer treatment
6. New study suggests promising drug combinations for sleeping sickness
7. Analysis of breast-cancer gene role offers promising target
8. Researchers report initial success in promising approach to prevent tooth decay
9. DNA highly promising predictor for successful treatment of alcoholics
10. Stem cells: Chemistry paves way toward promising therapies
11. Is liver damage down the TRAIL for a promising cancer therapy?

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: The long road promising malaria vaccine started NYU School Medicine

(Date:8/6/2015)... , August 6, 2015 ... (SMI) shows the world,s first Eye Tracking Integration ... Moverio BT-200 see-through head mounted display and on SMI,s ... quality and efficiency is brought to personalized visualization and ... first time, professionals and researchers can integrate gaze, and ...
(Date:8/5/2015)... August 5, 2015 According to ... Management Market by Software, Services, Vertical (BFSI, Airport, IT & ... - Global Forecast to 2020", published by MarketsandMarkets, defines ... globally into various segments. The global PIAM Market is ... $546.2 Million by 2019, at a CAGR of 14.9 ...
(Date:8/5/2015)... VIEW, Calif. , Aug. 5, 2015 ... exhibits continuous growth in applications, penetration into newer sectors, ... after year. The global biosensors space has seen the ... exited the market so far. (Photo - ... Frost & Sullivan, Analysis of the Global Biosensors ...
Breaking Biology News(10 mins):SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4
(Date:9/1/2015)... 2015 Shire plc (LSE: SHP, NASDAQ: ... to its Board of Directors as a Non-Executive Director. ... & Risk Committee of the Shire Board. Both appointments will ... previously served as Chairman, President and Chief Executive Officer of ... her 12-year tenure at D&B, she helped drive the transformation ...
(Date:8/31/2015)... 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the ... are for air emission abatement projects in North ... large order for a municipality in the Southern ... competitor,s system that failed to meet the customer,s requirements. This demonstrates ... Derek S. Webb , President and Chief Executive Officer.  ...
(Date:8/31/2015)... , Aug. 31, 2015 MabVax Therapeutics Holdings, ... announces that the Company,s lead antibody, HuMab 5B1, will ... separate presentations during the upcoming World Molecular Imaging Congress ... September 2-5, 2015. Researchers from the Department of Radiology ... results on the use of MabVax,s lead antibody as ...
(Date:8/31/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/k6lcp2/mexico_biomedical ) ... Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Mexico Biomedical Sensors market is estimated at $0.20 billion ... period 2014-2020 The near future will bring ... of each individual. These sensors can be set to ...
Breaking Biology Technology:Shire Appoints Sara Mathew to Board of Directors 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4Mexico Biomedical Sensors Market Report 2015-2020 2
Cached News: